Circulating Follistatin in Patients with Chronic Kidney Disease

Miyamoto, Tetsu; Carrero, Juan Jesús; Qureshi, Abdul Rashid; Anderstam, Björn; Heimbürger, Olof; Bárány, Peter; Lindholm, Bengt; Stenvinkel, Peter

doi:10.2215/cjn.10511110

Cited by 40 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several studies follistatin was not found to reflect dynapenia in older women or men [2, 31]. Interestingly, Miyamoto et al reported negative association between plasma follistatin and muscle strength in patients with chronic kidney disease, which is not consistent with observed effects of follistatin in inducing muscle hypertrophy [38]. Likewise, Liaw et al [35] found a negative correlation between follistatin and gait speed among older adults.…”

Section: Discussionmentioning

confidence: 99%

Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men

et al. 2018

View full text Add to dashboard Cite

BackgroundMyostatin, its inhibitor follistatin, and growth/differentiation factor 11 (GDF11) have been proposed as factors that could potentially modify biological aging. The study aimed to test whether there is a relationship between these plasma circulating proteins and muscle strength, power and optimal shortening velocity (υopt) of older adults.MethodsThe cross-sectional study included 56 women and 45 men aged 60 years and older. Every participant underwent examination which included anthropometric and bioimpedance analysis measurements, functional and cognitive performance tests, muscle strength of upper and lower extremities, muscle power testing with two different methods and blood analyses.ResultsWomen had higher plasma levels of myostatin and GDF11 than men. Men had higher plasma level of follistatin than women. In women, plasma level of myostatin was negatively correlated with left handgrip strength and υopt. Follistatin was negatively correlated with maximum power output (Pmax), power relative to kg of body mass (Pmax∙kg− 1) (friction-loaded cycle ergometer) and power at 70% of the 1-repetition maximum (1RM) strength value (P70%) of leg press (Keiser pneumatic resistance training equipment), and positively correlated with the Timed Up & Go (TUG) test. GDF11 was negatively correlated with body mass, body mass index, waist circumference, fat mass and the percentage of body fat. In men, there were no significant correlations observed between circulating plasma proteins and muscle function measures.ConclusionsThe circulating plasma myostatin and follistatin are negatively associated with muscle function in older women. There is stronger relationship between these proteins and muscle power than muscle strength. GDF11 has a higher association with the body mass and composition than muscle function in older women.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Another study also reported that serum levels of follistatin were not different among young males, older men with mild sarcopenia, and older men with severe sarcopenia [ 40 ]. However, a negative correlation between follistatin and gait speed was observed in older adults and patients with chronic kidney disease [ 47 , 48 ]. These conflicting results might be affected by the fact that TGF-β member (e.g., GDF-8, GDF-15, and Activin A) status may be accompanied by an increase in follistatin [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

“…However, a negative correlation between follistatin and gait speed was observed in older adults and patients with chronic kidney disease [ 47 , 48 ]. These conflicting results might be affected by the fact that TGF-β member (e.g., GDF-8, GDF-15, and Activin A) status may be accompanied by an increase in follistatin [ 47 ]. However, the present study was unable to address the question of the causality of muscle growth factors in sarcopenia.…”

Section: Discussionmentioning

confidence: 99%

Comparisons of Muscle Quality and Muscle Growth Factor Between Sarcopenic and Non-Sarcopenic Older Women

Seo

Jung

Kim

et al. 2020

IJERPH

View full text Add to dashboard Cite

Sarcopenia, an age-related disease, is one of the important health problems in the elderly and the prevalence of sarcopenia is rapidly increased among the Korean population. This study examined the muscle quality and muscle growth factors of elderly women to identify the potential diagnostic tool for sarcopenia. One hundred and thirty-six elderly women, aged over 65 years old, initially enrolled, but only 59 participants who met the criteria (sarcopenic group, n = 27; non-sarcopenic group, n = 32) completed the study. Muscle quality assessment included thigh cross-sectional computed tomography scan and maximal isometric muscle strength. Muscle growth factors such as GDF-15, myostatin, activin A, and follistatin were analyzed, and a battery of Senior Fitness Test was used to examine functional fitness. The statistical significance level was set at 0.05. Elderly women with sarcopenia had a lower thigh muscle volume (−20.1%), and a higher thigh intermuscular adipose tissue (15.8%) than those of the non-sarcopenic group (p < 0.05). However, no significant differences in muscle growth factors were observed between the groups. Muscle quality variables including maximal voluntary isometric contraction (OR: 0.968, p < 0.001), relative maximal voluntary isometric contraction (OR: 0.989, p < 0.05), thigh muscle volume (OR: 0.836, p < 0.001), and thigh intermuscular adipose tissue (OR: 1.138, p < 0.05) were associated with a risk of sarcopenia. Our findings suggest that the sarcopenic group exhibits a poor thigh muscle quality in comparison with the non-sarcopenic group. Muscle quality assessment can be utilized for sarcopenia identification, but our study remains inconclusive for the causality of muscle growth factors in sarcopenia.

show abstract

“…Myostatin, a protein that suppresses muscle growth, is another potential therapeutic target to inhibit. We recently showed that circulating levels of follistatin, a myostatin binder, were increased in wasted and inflamed incident dialysis patients, and negatively associated with muscle strength (7), suggesting a potential role of this molecular pathway in uremic PEW. In mice with CKD, myostatin inhibition by antimyostatin peptibody not only suppressed IL-6 and TNF but also prevented muscle atrophy (8).…”

Section: Pharmacological and Nutritional Treatment Of Uremic Inflammamentioning

confidence: 99%

“…Several names have been previously used to refer to this syndrome e.g., uremic malnutrition (5), protein-energy malnutri-tion (6), or malnutrition inflammation complex (1). To come to a more exact definition, the International Society of Renal Nutrition and Metabolism proposed the term protein energy wasting (PEW) (7). This nomenclature more accurately reflects the clinical syndrome.…”

mentioning

confidence: 99%